Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 19M | 12M | 2M | 4M | 31M |
| Gross Profit | 19M | 11M | -22M | -9M | 11M |
| Operating Income | -8M | -12M | -29M | -16M | 3M |
| EBITDA | -7M | -10M | -29M | -16M | 4M |
| Net Income | -6M | -11M | -27M | -15M | 3M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$74.46
+5.83% today
1Y Change
+880.51%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sol-Gel Technologies Ltd. (SLGL) is a Healthcare stock with a market cap of $210.00M and listed on NASDAQ. The stock last traded around $74.46 and up 880.5% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +68.0%, EPS growth of -478.9%, a dividend yield of 0.0%. What stands out right now is revenue +68.0%, EPS -478.9%, free cash flow +102.0% with operating margin 54.4% and ROIC 43.5%. Valuation already assumes a fairly strong business story at price/sales 11.0. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines SLGL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SLGL
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SLGL Max Drawdown
-35.38%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SLGL and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$31.3M
+705.4% YoY
FY Net Income
$3.2M
+121.6% YoY
Free Cash Flow
-$7.8M
+18.9% YoY
Revenue Growth
+68.0%
EPS Growth
-478.9%
Gross Margin
100.0%
Net Margin
-31.6%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 19M | 12M | 2M | 4M | 31M |
| Gross Profit | 19M | 11M | -22M | -9M | 11M |
| Operating Income | -8M | -12M | -29M | -16M | 3M |
| EBITDA | -7M | -10M | -29M | -16M | 4M |
| Net Income | -6M | -11M | -27M | -15M | 3M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 11M | 19M | 8M | 12M | 20M |
| Total Assets | 30M | 36M | 45M | 47M | 69M |
| Total Liabilities | 7M | 7M | 7M | 4M | 14M |
| Shareholder Equity | 23M | 29M | 39M | 42M | 56M |
| Total Debt | 991K | 1M | 2M | 772K | 2M |
| Net Debt | -10M | -18M | -6M | -12M | -18M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
8M
+18.9% YoY
Capital Expenditures
143K
+16.4% YoY
Free Cash Flow
8M
+18.9% YoY
Key ratios
Gross Margin
100.0%
Operating Margin
54.4%
Net Margin
-31.6%
ROE
-24.3%
Debt / Equity
0.04x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.